ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Cleveland, OH, USA:

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...

Enrolling
Mucosal Melanoma
Melanoma
Drug: Phase 1b: APG-115+pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Cleveland, Ohio, United States and 20 other locations

Locations recently updated

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Cleveland, Ohio, United States and 31 other locations

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Cleveland, Ohio, United States of America and 49 other locations

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

participants with a type of skin cancer known as melanoma.The objective of this study is to see if the combination of fianlimab and cemipli...

Enrolling
Melanoma
Drug: pembrolizumab
Drug: cemiplimab

Phase 2, Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Cleveland, Ohio, United States and 9 other locations

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Cleveland, Ohio, United States and 65 other locations

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 171 other locations

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 189 other locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 128 other locations

Locations recently updated

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the...

Enrolling
Melanoma
Drug: Pembrolizumab
Drug: Fianlimab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Cleveland, Ohio, United States and 206 other locations

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

(PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma...

Active, not recruiting
Advanced Melanoma
Drug: Pembrolizumab
Biological: Autogene cevumeran

Phase 2

Genentech
Genentech

Cleveland, Ohio, United States and 56 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems